natgillin/translations-raw huggingface dataset:
Before the initiation of STAYVEER treatment in women of childbearing potential, the absence of pregnancy should be checked, appropriate advice on reliable methods of contraception provided, and reliable contraception initiated. 
Pred začetkom zdravljenja z zdravilom STAYVEER je treba pri ženskah v rodni dobi izključiti nosečnost, jim nuditi ustrezen nasvet v zvezi z zanesljivimi načini kontracepcije in začeti z zanesljivo kontracepcijo.
The impact of moderately impaired liver function (Child-Pugh class B) on the pharmacokinetics of bosentan and its primary metabolite Ro 48-5033 was investigated in a study including 5 patients with pulmonary hypertension associated with portal hypertension and Child-Pugh class B hepatic impairment, and 3 patients with PAH from other causes and normal liver function. 
Vpliv zmerno okvarjenega delovanja ledvic (razred B po klasifikaciji Child-Pugh) na farmakokinetiko bosentana in njegov primarni presnovek Ro 48-5033 so raziskali v študiji, v katero je bilo vključenih 5 bolnikov s pljučno hipertenzijo, povezano s portalno hipertenzijo in okvarjenim delovanjem jeter razreda B po klasifikaciji Child-Pugh, in 3 bolniki s PAH zaradi drugih razlogov in normalnim delovanjem jeter.
Therefore, you must not take STAYVEER if you are pregnant and you must also not become pregnant while taking STAYVEER. 
Zato tega zdravila ne smete jemati, če ste noseči, v času, ko ga jemljete, pa tudi ne smete zanositi.
Survival estimates were lower in the subgroup of patients with PAH secondary to systemic sclerosis. 
Ocenjeno preživetje je bilo manjše v podskupini bolnikov s PAH, ki se je razvila zaradi sistemske skleroze.
AC-052-356 was an open-label, uncontrolled study; 10 of the 19 paediatric patients were on concomitant bosentan and epoprostenol therapy during the 12week study. 
AC-052-356 je bila nenadzorovana študija z znanim zdravilom; 10 od 19 pediatričnih bolnikov je v času 12-tedenske študije sočasno jemalo bosentan in epoprostenol.
• Pulmonary arterial hypertension (PAH): PAH is a disease of severe narrowing of the blood vessels in the lungs resulting in high blood pressure in the blood vessels (the pulmonary arteries) that carry blood from the heart to the lungs. 
PAH je bolezen hude zožitve krvnih žil v pljučih, ki povzroči visok krvni tlak v krvnih žilah v pljučih (pljučnih arterijah), ki prenašajo kri iz srca v pljuča.
Rare (may affect up to one in 1000 people): 
Redki (prizadenejo lahko do 1 od 1.000 bolnikov):
After 16 weeks' treatment, there were significant improvements from baseline in exercise capacity: the mean increase in 6-minute walk distance was 91.4 metres from 332.6 metres on average at baseline (p < 0.001). 
Po 16 tednih so opazili pomembna izboljšanja od izhodiščne zmogljivosti za telesno vadbo: povprečno povečanje razdalje, prehojene v 6-minutnem preizkusu s hojo: 91,4 metra s povprečne izhodiščne razdalje 332,6 metra (p < 0,001).
In both studies, patients on bosentan were less likely to develop multiple new digital ulcers during the study and took longer to develop each successive new digital ulcer than did those on placebo. 
V obeh študijah so bolniki, zdravljeni z bosentanom, med študijo razvili manj novih razjed na prstih in so potrebovali dlje, da so razvili vsako naslednjo razjedo kot bolniki, zdravljeni s placebom.
For children aged 1 year and older, treatment with STAYVEER is usually started with 2 mg per kg bodyweight twice daily (morning and evening). 
Za otroke, stare 1 leto in več, se zdravljenje z zdravilom STAYVEER običajno začne z 2 mg na kg telesne mase dvakrat dnevno (zjutraj in zvečer).
Your liver and blood values will be monitored during treatment with STAYVEER (see section 2). 
Med zdravljenjem z zdravilom STAYVEER bodo spremljali vaše jetrne in krvne vrednosti (glejte poglavje 2).
The overall goal of the Patient Alert Card is to educate patients on important safety information that they need to be aware of before and during treatment with STAYVEER. 
Glavni namen opozorilne kartice za bolnika je bolnike poučiti o pomembnih varnostnih informacijah, s katerimi morajo biti seznanjeni pred in med zdravljenjem z zdravilom STAYVEER.
Patients with suboptimal response to inhaled nitric oxide (iNO) despite at least 4 hours of continuous treatment were treated with bosentan dispersible tablets at 2 mg/kg twice daily (N = 13) or placebo (N = 8) via nasogastric tube as add-on therapy on top of iNO until complete weaning of iNO or until treatment failure (defined as need for extra-corporeal membrane oxygenation [ECMO] or initiation of alternative pulmonary vasodilator), and for a maximum of 14 days. 
Bolniki s suboptimalnim odzivom na vdihavanje dušikovega oksida (iNO) kljub vsaj 4 ure trajajoči neprekinjeni terapiji so prejemali disperzibilne tablete bosentana 2 mg/kg dvakrat dnevno (N = 13) ali placebo (N = 8) po nazogastrični sondi kot dodatno terapijo poleg iNO do popolne ukinitve iNO ali do neuspeha zdravljenja (opredeljen kot potreba po izventelesni membranski oksigenaciji [ECMO] ali uvedba alternativnega pljučnega vazodilatatorja), in to največ 14 dni.
STAYVEER is used to treat: 
Zdravilo STAYVEER uporabljamo za zdravljenje:
The Kaplan-Meier event-free estimate for worsening of PAH (death, lung transplantation, or hospitalisation for PAH worsening) at 2 years was 78.9%. 
Po Kaplan-Meierjevem izračunu je bilo po 2 letih brez dogodkov poslabšanja PAH (smrt, presaditev pljuč ali hospitalizacija zaradi poslabšanja PAH) 78,9 % bolnikov.
When treatment with STAYVEER is initiated in patients who require ritonavir-boosted protease inhibitors, the patient's tolerability of STAYVEER should be closely monitored with special attention, at the beginning of the initiation phase, to the risk of hypotension and to liver function tests. 
Ko se zdravljenje z zdravilom STAYVEER uvede pri bolnikih, ki potrebujejo zaviralce proteaze, pospešene z ritonavirjem, je treba prenašanje zdravila STAYVEER pri teh bolnikih skrbno nadzirati s posebno pozornostjo na začetku faze uvajanja v zvezi s tveganjem hipotenzije in preiskavami delovanja jeter.
• Gastrooesophageal reflux disease (acid reflux) 
• gastroezofagealna refluksna bolezen (refluks kisline)
Bosentan has been shown to be teratogenic in rats at plasma levels higher than 1.5 times the plasma concentrations achieved at the therapeutic dose in humans. 
Za bosentan so ugotovili, da je teratogen pri podganah pri plazemskih koncentracijah, več kot 1,5-krat višjih od plazemskih koncentracij, doseženih pri ljudeh po terapevtskih odmerkih.
Development of testicular tubular atrophy and impaired fertility has been linked with chronic administration of endothelin receptor antagonists in rodents. 
Razvoj tubularne atrofije testisov in zmanjšana plodnost sta bila pri glodavcih povezana s kroničnim dajanjem antagonistov endotelinskih receptorjev.
If you forget to take STAYVEER 
Če ste pozabili vzeti zdravilo STAYVEER
Both glibenclamide and bosentan inhibit the bile salt export pump, which could explain the elevated aminotransferases. 
Tako glibenklamid kot bosentan zavirata črpalko žolčnih soli, kar bi lahko razložilo povišanje aminotransferaz.
The effect of bosentan on reduction of the number of new digital ulcers was more pronounced in patients with multiple digital ulcers. 
Učinek bosentana na zmanjšanje števila novih razjed prstov je bil jasnejši pri bolnikih z več razjedami.
STAYVEER can be taken with or without food. 
Zdravilo STAYVEER lahko jemljete s hrano ali brez nje.
Dyspnoea measurement during walk tests showed an improvement in bosentan-treated patients. 
Meritve dispneje med preskusi s hojo so pokazale izboljšanje pri bolnikih, ki so jemali bosentan.
After an increase in dose, an additional test will be done after 2 weeks. 
Po zvišanju odmerka zdravila bo po 2 tednih opravljena še ena dodatna preiskava.
Appropriate precautions must be taken for women of childbearing potential (see sections 4.3, 4.4 and 4.6). 
Pri ženskah v rodni dobi moramo upoštevati ustrezne varnostne ukrepe (glejte poglavja 4.3, 4.4 in 4.6).
• hormonal contraceptives, which are not effective as the sole method of contraception when you take STAYVEER. 
• hormonsko kontracepcijo, ki kot edini način preprečevanja zanositve ni učinkovit, če jemljete zdravilo STAYVEER.
In patients with mildly impaired liver function (Child-Pugh class A) no relevant changes in the pharmacokinetics have been observed. 
Okvarjeno delovanje jeter Pri bolnikih z blago okvarjenim delovanjem jeter (Child-Pugh razred A) niso opazili kakih pomembnih sprememb v farmakokinetiki.
• Monthly pregnancy tests are recommended during treatment to allow early detection of pregnancy 
• se med zdravljenjem zaradi zgodnjega ugotavljanja nosečnosti priporočajo mesečni testi nosečnosti.
If you stop taking STAYVEER 
Če ste prenehali jemati zdravilo STAYVEER
Control was placebo plus current therapy. 
Kontrolna skupina je prejemala placebo in redno terapijo.
A careful benefit/risk assessment should be made, taking into consideration the liver toxicity of bosentan (see sections 4.4 and 4.8). 
Skrbno moramo oceniti razmerje med koristjo in tveganjem, pri čemer upoštevamo toksičen vpliv bosentana za jetra (glejte poglavji 4.4 in 4.8).
Similar effects would be expected with other ritonavir-boosted protease inhibitors (see section 4.4). 
Podobni učinki se pričakujejo z drugimi zaviralci proteaze, ki jih okrepi ritonavir (glejte poglavje 4.4).
Fluconazole and other inhibitors of both CYP2C9 and CYP3A4: Co-administration with fluconazole, which inhibits mainly CYP2C9, but to some extent also CYP3A4, could lead to large increases in plasma concentrations of bosentan. 
Flukonazol in drugi zaviralci CYP2C9 in CYP3A4: Sočasno dajanje s flukonazolom, ki zavira predvsem CYP2C9, do določene mere pa tudi CYP3A4, lahko povzroči do veliko povišanje plazemskih koncentracij bosentana.
33 of these patients were provided with continued treatment with bosentan dispersible tablets at a dose of 4 mg/kg twice daily in the FUTURE 2 uncontrolled extension phase for a median overall treatment duration of 2.3 years (range: 0.2 to 5.0 years). 
33 od teh bolnikov je nadaljevalo zdravljenje z disperzibilnimi tabletami bosentana v odmerku 4 mg/kg dvakrat dnevno v nenadzorovani podaljšani fazi študije FUTURE 2, kjer je skupno mediano trajanje zdravljenja znašalo 2,3 leta (razpon: 0,2 do 5,0 let).
In this study, fluid retention was manifested by early weight gain, decreased haemoglobin concentration and increased incidence of leg oedema. 
V tej študiji se je zadrževanje tekočine pokazalo kot zgodnje povečanje telesne mase, znižanje koncentracije hemoglobina in povečanje števila primerov edemov nog.
There are no studies to demonstrate beneficial effects of STAYVEER treatment on survival. 
Raziskav, s katerimi bi pokazali koristne učinke zdravljenja z zdravilom STAYVEER na preživetje bolnikov, ni.
Teratogenic effects, including malformations of the head and face and of the major vessels, were dose dependent. 
kot so malformacije glave, obraza in velikih žil, so bili odvisni od odmerka.
Blood tests for anaemia 
Krvne preiskave za anemijo
In study AC-052-373 (FUTURE 3), using dispersible tablets, the exposure to bosentan in the patients treated with 2 mg/kg twice daily was comparable to that in the FUTURE 1 study. 
V študiji AC-052-373 (FUTURE 3) z disperzibilnimi tabletami je bila izpostavljenost bosentanu pri bolnikih, zdravljenih z 2 mg/kg dvakrat dnevno, primerljiva s tisto v študiji FUTURE 1.
Do not take a double dose to make up for forgotten tablets. 
Ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnjega.
White high-density polyethylene bottles with a silica gel desiccant containing 56 film-coated tablets. 
Bele plastenke iz polietilena visoke gostote s silikagelnim sušilom, ki vsebujejo 56 filmsko obloženih tablet.
• Elevated liver function tests with hepatitis (inflammation of the liver) including possible exacerbation of underlying hepatitis and/or jaundice (yellowing of the skin or the whites of the eyes) 
• zvišani izsledki preiskav delovanja jeter s hepatitisom (vnetjem jeter), vključno z možnim poslabšanjem obstoječega hepatitisa, in/ali zlatenica (porumenelost kože ali beločnice v očeh)
For further details please refer to section 4.5. 
Za podrobnosti glejte poglavje 4.5.
4 years For white high-density polyethylene bottles, use within 30 days after the first opening. 
4 leta Vsebino belih plastenk iz polietilena visoke gostote porabite v 30 dneh po prvem odprtju.
Should this occur, starting treatment with diuretics is recommended, or the dose of existing diuretics should be increased. 
Če pride do tega, priporočamo uvedbo zdravljenja z diuretiki ali povišanje odmerka diuretika, ki ga bolnik že uporablja.
However, STAYVEER may induce hypotension, with symptoms of dizziness, blurred vision or syncope that could affect the ability to drive or use machines. 
Zdravilo STAYVEER lahko povzroči hipotenzijo s simptomi omotice, zamegljenega vida ali sinkope, ki bi lahko vplivala na sposobnost vožnje in upravljanja strojev.
In the event of associated clinical symptoms of liver injury, i.e., nausea, vomiting, fever, abdominal pain, jaundice, unusual lethargy or fatigue, flu-like syndrome (arthralgia, myalgia, fever), treatment must be stopped and re-introduction of STAYVEER is not to be considered. 
V primeru kliničnih simptomov, povezanih z okvarjenim delovanjem jeter, npr. slabost, bruhanje, povišana telesna temperatura, bolečine v trebuhu, zlatenica, nenavadna letargija ali utrujenost, gripi podobni simptomi (bolečine v sklepih, bolečine v mišicah, povišana telesna temperatura), moramo zdravljenje prekiniti in ponovna uvedba zdravljenja z zdravilom STAYVEER ni dovoljena.
In the post-marketing period, cases of anaemia requiring red blood cell transfusion have been reported (see section 4.8). 
V obdobju po uvedbi zdravila na trg so poročali o primerih anemije, zaradi katere je bila potrebna transfuzija eritrocitov (glejte poglavje 4.8).
Oral use Read the package leaflet before use 
Peroralna uporaba Pred uporabo preberite priloženo navodilo!
The most frequent adverse events in the bosentan- and placebo-treated patients were, respectively, anaemia or haemoglobin decrease (7 and 2 patients), generalised oedema (3 and 0 patients), and vomiting (2 and 0 patients). 
Najpogostejši neželeni učinki pri bolnikih, zdravljenih z bosentanom oziroma placebom, so bili v navedenem zaporedju: anemija ali znižanje vrednosti hemoglobina (7 oz. 2 bolnika), generalizirani edem (3 oz. 0 bolnikov) in bruhanje (2 oz. 0 bolnikov).
• jaundice (yellowing of your skin or the whites of your eyes) 
• zlatenico (porumenelost kože ali beločnice v očeh)
Liver aminotransferase levels must be measured prior to initiation of treatment and subsequently at monthly intervals for the duration of treatment with STAYVEER. 
Ravni jetrnih aminotransferaz moramo izmeriti pred začetkom zdravljenja in nato redno enkrat na mesec ves čas zdravljenja z zdravilom STAYVEER.
STAYVEER has no or negligible influence on the ability to drive and use machines. 
Zdravilo STAYVEER nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Birth control based on hormones - such as oral contraceptives or birth control pills, hormone injections, implants, or birth control skin patches don't reliably prevent pregnancy in women who are taking STAYVEER. 
Hormonske kontracepcijske metode, kot so peroralni kontraceptivi ali kontracepcijske tabletke, hormonske injekcije, vsadki ali kožni obliži nosečnosti ne preprečujejo zanesljivo pri ženskah, ki jemljejo zdravilo STAYVEER.
The study was primarily designed as a pharmacokinetic study (see section 5.2), and efficacy endpoints were only exploratory. 
Študija je bila zasnovana predvsem kot farmakokinetična študija (glejte poglavje 5.2) in opazovani dogodki so bili zgolj raziskovalni.
Anaemia may occasionally require blood transfusion 
Zaradi anemije je treba bolnike včasih zdraviti s krvno transfuzijo.
STAYVEER 62.5 mg film-coated tablets EU/1/13/832/001 
STAYVEER 62,5 mg filmsko obložene tablete EU/1/13/832/001
Patients were divided into three body-weight groups and dosed with bosentan at approximately 2 mg/kg twice daily for 12 weeks. 
Bolnike so razvrstili v tri skupine glede na telesno maso in jim določili odmerek bosentana približno 2 mg/kg dvakrat dnevno, ki so ga prejemali 12 tednov.
Adverse events of liver abnormalities and anaemia/haemoglobin decrease occurred in 9% and 5% of patients, respectively. 
Neželeni učinki v obliki nenormalnih jetrnih testov in anemije/znižane vrednosti hemoglobina so se pojavili pri 9 % oziroma 5 % bolnikov.
• if you are taking cyclosporine A (a medicine used after a transplant or to treat psoriasis) 
• če jemljete ciklosporin A (zdravilo, ki se uporablja po presaditvi ali za zdravljenje luskavice).
The median bosentan and placebo treatment duration was, respectively, 4.5 days (range 0.5-10.0 days) and 4.0 days (range 2.5-6.5 days). 
Mediana trajanja zdravljenja z bosentanom in placebom je bila 4,5 dni (razpon 0,5-10,0 dni) oziroma 4,0 dni (razpon 2,5-6,5 dni).
This metabolite is mainly excreted unchanged via the bile. 
Ta presnovek se večinoma izloči v nespremenjeni obliki z žolčem.
OUTER CARTON/BLISTERS NAME OF THE MEDICINAL PRODUCT 
ZUNANJA ŠKATLA/PRETISNI OMOT IME ZDRAVILA
The possibility of altered efficacy of medicinal products metabolised by these isoenzymes should be considered. 
Upoštevajte možnost spremenjene učinkovitosti zdravil, ki jih presnavljajo ti izoencimi.
In study AC-052-331, during 24 weeks of double-blind therapy, the corresponding figures were 1.9 vs 2.7 new digital ulcers, respectively (p = 0.0351). 
V študiji AC-052-331 so bile ustrezne številke med 24-tedensko dvojno slepo terapijo 1,9 proti 2,7 novih razjed prstov v enakem zaporedju (p = 0,0351).
years to 11 years old, 15 (23.4%) were between 1 and 2 years old, and 6 (9.4%) were between 3 months and 1 year old. 
43 otrok (67,2 %) je bilo starih od ≥ 2 leti do 11 let, 15 (23,4 %) je bilo starih od 1 do 2 leti, 6 (9,4 %) pa je bilo starih od 3 mesece do 1 leta.
Bosentan was negative in tests for genotoxicity. 
Test genotoksičnosti bosentana je bil negativen.
In the FUTURE-4 study, 6 out of 13 bosentan-treated neonates with PPHN experienced a decrease in haemoglobin from within the reference range at baseline to below the lower limit of normal during the treatment. 
V študiji FUTURE-4 se je pri 6 od 13 novorojenčkov s PPHN, zdravljenih z bosentanom, hemoglobin med zdravljenjem znižal od vrednosti znotraj referenčnega razpona ob izhodišču do vrednosti pod spodnjo mejo normale.
In the pooled analysis of 100 PAH children from uncontrolled paediatric studies FUTURE 1/2 and FUTURE 3/Extension, a decrease in haemoglobin concentration from baseline to below 10 g/dL was reported in 10.0% of patients. 
V skupni analizi 100 otrok s PAH iz nenadzorovanih pediatričnih študij FUTURE 1/2 in FUTURE 3/podaljšanje, so o znižanih koncentracijah hemoglobina od izhodiščne vrednosti do manj kot 10 g/dl poročali pri 10,0 % bolnikov.
The PAH for which STAYVEER is indicated can be: 
PAH, zaradi katere je zdravilo STAYVEER predpisano, je lahko:
At baseline in FUTURE 1, 9 patients were taking epoprostenol. 
FUTURE 1 9 bolnikov jemalo epoprostenol.
In study AC-052-331, patients had to have at least one digital ulcer of recent onset, and across the two studies 85% of patients had ongoing digital ulcer disease at baseline. 
V študiji AC-052-331 so bolniki morali imeti vsaj eno razjedo na prstih, ki je nastopila nedavno in v obeh študijah je 85% bolnikov imelo nastajajoče razjede prstov.
The steady-state AUC of bosentan was 9% higher and the AUC of the active metabolite, Ro 48-5033, was 33% higher in patients with mild hepatic impairment than in healthy volunteers. 
V stanju dinamičnega ravnovesja je bila vrednost AUCτ bosentana za 9 % večja in vrednost AUCτ za aktivni presnovek, Ro 48-5033, za 33 % večja pri bolnikih z blago okvarjenim delovanjem jeter kot pri zdravih prostovoljcih.
At steady state, AUCτ was 6,165 ng·h/mL (CV: 133%, n = 7), which is similar to the exposure observed in adult PAH patients receiving 125 mg twice daily and taking into account a blood/plasma distribution ratio of 0.6. 
6.165 ng·h/ml (CV: 133 %, n = 7), kar je podobno izpostavljenosti, ki so jo opazili pri odraslih bolnikih s PAH, ki so prejemali 125 mg dvakrat dnevno, in upoštevaje razmerje porazdelitve v krvi/plazmi 0,6.
In a study investigating the effects of bosentan on testicular function in male PAH patients, 8 out of 24 patients showed a decreased sperm concentration from baseline of at least 42% after 3 or 6 months of treatment with bosentan. 
V študiji, ki je preučevala učinke bosentana na funkcijo testisov pri moških bolnikih s PAH, so po 3 ali 6 mesecih zdravljenja z bosentanom pri 8 od 24 bolnikov ugotovili zmanjšano koncentracijo sperme za najmanj 42 % od izhodiščne vrednosti.
The same recommendations apply to re-introduction of STAYVEER after treatment interruption (see section 
Enaka priporočila veljajo ob ponovni uvedbi zdravila STAYVEER po prekinitvi zdravljenja (glejte poglavje
Inhibition by ritonavir of transport protein-mediated uptake into hepatocytes and of CYP3A4, thereby reducing the clearance of bosentan, most likely causes this interaction. 
Zaviranje privzema s transportnimi beljakovinami v hepatocite in CYP3A4, ki ga povzroči ritonavir, kar zmanjša očistek bosentana, najverjetneje povzroči to medsebojno delovanje.
3 Headache was reported in 11.5% of patients on bosentan and 9.8% of patients on placebo. 
3 O glavobolu so poročali pri 11,5 % bolnikov na bosentanu in 9,8 % bolnikov na placebu.
- The other ingredients in the tablet core are maize starch, pregelatinised starch, sodium starch glycolate (Type A), povidone, glycerol dibehenate and magnesium stearate. 
- Druge sestavine v jedru tablete so koruzni škrob, predgelirani škrob, natrijev karboksimetilškrob (vrsta A), povidon, glicerildibehenat in magnezijev stearat.
Dosing bosentan 2 mg/kg three times daily did not increase exposure; daily exposure was 7,275 ng·h/mL (CV: 83%, n = 27). 
Odmerjanje bosentana 2 mg/kg trikrat dnevno ni povečalo izpostavljenosti, dnevna izpostavljenost je bila 7.275·ng/ml (CV: 83 %, n = 27).
• Anaphylaxis (general allergic reaction), angioedema (swelling, most commonly around the eyes, 
• anafilaksa (splošna alergijska reakcija), angioedem (oteklost, običajno okoli oči, ustnic, jezika ali grla)
In healthy subjects, bosentan displays dose- and time-dependent pharmacokinetics. 
Pri zdravih osebah je farmakokinetika bosentana odvisna od odmerka in časa.
However, when combined with a CYP3A4 inhibitor, patients who are poor metabolisers of CYP2C9 are at risk of increases in bosentan plasma concentrations that may be of higher magnitude, thus leading to potential harmful adverse events. 
V kombinaciji z zaviralcem CYP3A4 obstaja pri bolnikih, ki slabo presnavljajo s CYP2C9, tveganje še večjega povišanja plazemske koncentracije bosentana, kar lahko povzroči potencialno škodljive neželene dogodke.
There is limited clinical study experience with the use of STAYVEER in patients with PAH associated with HIV infection, treated with antiretroviral medicinal products (see section 5.1). 
O uporabi zdravila STAYVEER pri bolnikih s PAH, povezanim z okužbo s HIV, ki se zdravijo s protiretrovirusnimi zdravili, imamo omejene izkušnje iz kliničnih študij (glejte poglavje 5.1).
Your monthly liver blood test schedule: 
Urnik mesečnih preiskav krvi za oceno delovanja jeter:
• cyclosporine A (a medicine used after transplants and to treat psoriasis), which must not be used together with STAYVEER. 
• ciklosporin A (zdravilo, ki se uporablja po presaditvah in za zdravljenje luskavice), ki ga ne smete uporabljati skupaj z zdravilom STAYVEER,
The efficacy of STAYVEER has not been established in patients with severe PAH. 
Učinkovitost zdravila STAYVEER pri bolnikih s hudo PAH ni bila ugotovljena.
STAYVEER is contraindicated in patients with moderate to severe hepatic impairment, i.e., Child-Pugh class B or C (see section 4.3). 
Zdravilo STAYVEER je kontraindicirano pri bolnikih z zmerno do hudo okvaro jeter, tj. razreda B ali C po klasifikaciji Child-Pugh (glejte poglavje 4.3).